Evaluation of antibacterial efficacy of sulfur nanoparticles alone and in combination with antibiotics against multidrug-resistant uropathogenic bacteria

Paralikar, Priti; Ingle, Avinash P.; Tiwari, Vaibhav; Golińska, Patrycja; Dahm, H.; Rai, Mahendra

doi:10.1080/10934529.2018.1558892

Cited by 33 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These five isolates demonstrate resistance to cefoxitin, characteristic of AmpC producers according to CLSI [16], but this enzyme was not evaluated at the time. The species presenting this resistance have been considered important species to nosocomial infections: Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae and these bacteria are commonly associated with multidrug-resistance [3,4,15]. K. pneumoniae (3/5) was obtained from pus and urine, E. coli (1/5) also was obtained from urine, and P. mirabilis (1/5) was isolated from a blood catheter.…”

Section: Resultsmentioning

confidence: 99%

“…In addition to the high rates of infection in hospitals, the growing resistance of these nosocomial pathogens to antimicrobials has an economic burden in the treatment of these infections. These pathogens have been reported resistant to important drugs to treat infectious diseases as cefotaxime, amoxicillin, nitrofurantoin, and trimethoprim plus sulfamethoxazole [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Conjugative plasmidic AmpC detected in Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae human clinical isolates from Portugal

et al. 2020

View full text Add to dashboard Cite

AmpC is a type of β-lactamase enzyme produced by bacteria; these enzymes are classified in Class C and Group 1, and these confer resistance to cephamycin. Enterobacterales producing AmpC are reported worldwide and have great clinical importance due to therapeutic restriction and epidemiological importance once the easy dissemination by plasmidic genes to other bacteria is a real threat. These genes are naturally found in some enterobacteria as Enterobacter cloacae, Morganella morganii, and Citrobacter freundii, but other species have demonstrated similar resistance phenotype of AmpC production. Genes carried in plasmids have been described in these species conferring resistance to cefoxitin and causing therapeutic failure in some bacterial infections. This work detected and described five clinical strains of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae that presented plasmid ampC (pAmpC) isolated from the north of Portugal collected in 2009. AmpC production was confirmed by inhibition of the enzyme by cloxacillin and boronic acid in agar diffusion tests. Also, PCR (polymerase chain reaction) was performed for the detection of gene universal to AmpC, bla ampC , and others to AmpC group: bla ACC , bla CIT , bla CMY , bla DHA , and bla EBC. The conjugation in liquid medium for 24 h was realized to determine if gene is localized in chromosome or plasmid. The isolates and their conjugants showed phenotypic characteristics and bla CMY and bla CIT were detected by PCR corroborating the AmpC characteristics observed in these bacteria. Confirmation of transfer of plasmid containing genes encoding AmpC is of high epidemiological relevance to the hospital studied and demonstrated the importance of AmpC surveillance and studies in hospital and community environments in order to choose the appropriate therapy for bacterial infections.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Conjugative plasmidic AmpC detected in Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae human clinical isolates from Portugal

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Antibiotic resistance is a growing worldwide human health issue, and alternative antimicrobial strategies are needed urgently. Several novel materials, including metal–organic frameworks, antimicrobial peptides, nanoparticles and combinations of these, have shown promise for new antimicrobial strategies, but metal‐based materials have low stability and/or can be highly toxic to mammalian cells and methods for targeted delivery of antimicrobial peptides are lacking. In this study, we demonstrate the potential of DNA origami nanostructures functionalized with aptamers as a vehicle for delivering active antimicrobial components in a target‐specific and efficient manner.…”

Section: Figurementioning

confidence: 99%

DNA Nanostructures for Targeted Antimicrobial Delivery

et al. 2020

View full text Add to dashboard Cite

We report the use of DNA origami nanostructures, functionalized with aptamers, as a vehicle for delivering the antibacterial enzyme lysozyme in a specific and efficient manner. We test the system against Gram‐positive (Bacillus subtilis) and Gram‐negative (Escherichia coli) targets. We use direct stochastic optical reconstruction microscopy (dSTORM) and atomic force microscopy (AFM) to characterize the DNA origami nanostructures and structured illumination microscopy (SIM) to assess the binding of the origami to the bacteria. We show that treatment with lysozyme‐functionalized origami slows bacterial growth more effectively than treatment with free lysozyme. Our study introduces DNA origami as a tool in the fight against antibiotic resistance, and our results demonstrate the specificity and efficiency of the nanostructure as a drug delivery vehicle.

show abstract

“…Antibiotic resistance is a growing worldwide human health issue, and alternative antimicrobial strategies are needed urgently. Several novel materials, including metal-organic frameworks, [1] antimicrobial peptides, [2] nanoparticles [3] and combinations of these, [4] have shown promise for new antimicrobial strategies, but metal-based materials have low stability and/or can be highly toxic to mammalian cells [5,6] and methods for targeted delivery of antimicrobial peptides are lacking. In this study, we demonstrate the potential of DNA origami nanostructures functionalized with aptamers as a vehicle for delivering active antimicrobial components in a target-specific and efficient manner.…”

mentioning

confidence: 99%